search
Back to results

Long-term Effectiveness of Non-ablative Er: YAG Laser for Treatment of Stress Urinary Incontinence (SUI)

Primary Purpose

Stress Urinary Incontinence

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Non-ablative thermal-only Er:YAG laser therapy
Sponsored by
Adrian Gaspar
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stress Urinary Incontinence focused on measuring stress urinary incontinence, non-ablative Er:YAG laser

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult Female, 18 years of age or older
  • Clinical and urodynamic study (UDS) diagnosis of Stress Urinary Incontinence
  • No significant improvement in urinary incontinence from at least one previous conservative treatment, such as pelvic floor muscle training

Exclusion Criteria:

  • Pre-existing bladder pathology including prior radiation treatment
  • Pregnancy
  • BMI>35
  • Radical pelvic surgery or previous incontinence surgery
  • Urinary tract infection or other active infections of urinary tract or bladder
  • SUI III (VLPP > 60 cm H2O)
  • Any form of pelvic organ prolapse (POP) stage 2 or greater, according to POP-Q
  • Diagnosis of urge incontinence
  • Diagnosis of collagen disorders eg.benign joint hypermobility / Elhers-Danlos / Marfans etc.
  • Incomplete bladder emptying
  • Vesicovaginal fistula
  • Faecal incontinence
  • Unwillingness or inability to complete follow-up schedule
  • Unwillingness or inability to give Informed Consent
  • Failure to comply with diary requirements during extended baseline period

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Laser therapy

    Arm Description

    Non-ablative thermal-only Er:YAG laser treatment using IncontiLase® protocol.

    Outcomes

    Primary Outcome Measures

    Assessment of ICIQ-UI SF scores
    Change in mean test scores range = 0 - 21; low score = mild symptoms, high score = significant impact on quality of life.
    Assessment of 1 hour pad weight test
    The change in standardised 1 hour pad weight test from baseline to 36 months following treatment schedule.

    Secondary Outcome Measures

    Change in 24 hour pad weight test
    The change in standardised 24 hour pad weight test from baseline to 36 months following treatment schedule.
    Change in leakage frequency as assessed by 3 day voiding diary
    The change in leakage frequency from baseline to 36 months following treatment schedule.

    Full Information

    First Posted
    April 14, 2020
    Last Updated
    April 15, 2020
    Sponsor
    Adrian Gaspar
    Collaborators
    Fotona d.o.o.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04348994
    Brief Title
    Long-term Effectiveness of Non-ablative Er: YAG Laser for Treatment of Stress Urinary Incontinence (SUI)
    Official Title
    3-year Follow up of Patients With Stress Urinary Incontinence Treated With Minimally Invasive Er: YAG Laser
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2020
    Overall Recruitment Status
    Completed
    Study Start Date
    March 1, 2015 (Actual)
    Primary Completion Date
    September 1, 2018 (Actual)
    Study Completion Date
    December 31, 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Adrian Gaspar
    Collaborators
    Fotona d.o.o.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Study is designed to assess the long-term clinical effects and safety profile of non-ablative Er:YAG (IncontiLase®) laser treatment, the durability of the results and the optimal treatment regimen for mild-to-severe stages of genuine female stress urinary incontinence (SUI).
    Detailed Description
    All patients with urodynamically proven SUI, who have failed/declined conservative therapies will be informed about the study. They will be invited to attend a screening/baseline visit. At this visit, they will be asked to perform a standardised 1 hour pad test. Their medical history will be checked and they will undergo a clinical and vaginal examination, pregnancy test and dip stick urinalysis. If their 1 hour pad weight is >2g and they meet all other inclusion / exclusion criteria, they will be eligible for inclusion. They will receive detailed instructions for performing a 24 hour pad test, and will be asked to keep a 3 day voiding diary. They will be given the International Consultation on Incontinence Questionnaire Short Form (ICIQ-UI SF). Patients will then undergo 3 outpatient treatment visits. The timing of visits will be approximately 1 month apart. At each of their 3 outpatient appointments, they will be asked about any deleterious effects since their last appointment. Patients will receive 3 treatments in total. Patients will be invited to attend a follow-up visits 3, 6, 12 and 18 months after the 3rd treatment and asked to complete the 1 hour pad test, 24 hour pad test, 3 day voiding diary and ICIQ-SF questionnaire. At the 18-, 24- and 30-month follow up, they will be given an option to receive additional single session of non-ablative Er:YAG laser treatment. At each visit, and during additional visit after 36 months, they will be asked to complete all of the tests (1 hour pad test, 24 h hour pad test, 3 day voiding diary and ICIQ-UI SF).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Stress Urinary Incontinence
    Keywords
    stress urinary incontinence, non-ablative Er:YAG laser

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    43 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Laser therapy
    Arm Type
    Experimental
    Arm Description
    Non-ablative thermal-only Er:YAG laser treatment using IncontiLase® protocol.
    Intervention Type
    Device
    Intervention Name(s)
    Non-ablative thermal-only Er:YAG laser therapy
    Other Intervention Name(s)
    IncontiLase®
    Intervention Description
    Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®). Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions.
    Primary Outcome Measure Information:
    Title
    Assessment of ICIQ-UI SF scores
    Description
    Change in mean test scores range = 0 - 21; low score = mild symptoms, high score = significant impact on quality of life.
    Time Frame
    Baseline, 3, 6, 12, 18, 24, 30 and 36 months
    Title
    Assessment of 1 hour pad weight test
    Description
    The change in standardised 1 hour pad weight test from baseline to 36 months following treatment schedule.
    Time Frame
    Baseline, 3, 6, 12, 18, 24, 30 and 36 months
    Secondary Outcome Measure Information:
    Title
    Change in 24 hour pad weight test
    Description
    The change in standardised 24 hour pad weight test from baseline to 36 months following treatment schedule.
    Time Frame
    Baseline, 3, 6, 12, 18, 24, 30 and 36 months
    Title
    Change in leakage frequency as assessed by 3 day voiding diary
    Description
    The change in leakage frequency from baseline to 36 months following treatment schedule.
    Time Frame
    Baseline, 3, 6, 12, 18, 24, 30 and 36 months

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adult Female, 18 years of age or older Clinical and urodynamic study (UDS) diagnosis of Stress Urinary Incontinence No significant improvement in urinary incontinence from at least one previous conservative treatment, such as pelvic floor muscle training Exclusion Criteria: Pre-existing bladder pathology including prior radiation treatment Pregnancy BMI>35 Radical pelvic surgery or previous incontinence surgery Urinary tract infection or other active infections of urinary tract or bladder SUI III (VLPP > 60 cm H2O) Any form of pelvic organ prolapse (POP) stage 2 or greater, according to POP-Q Diagnosis of urge incontinence Diagnosis of collagen disorders eg.benign joint hypermobility / Elhers-Danlos / Marfans etc. Incomplete bladder emptying Vesicovaginal fistula Faecal incontinence Unwillingness or inability to complete follow-up schedule Unwillingness or inability to give Informed Consent Failure to comply with diary requirements during extended baseline period

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    35067817
    Citation
    Gaspar A, Koron N, Silva J, Brandi H. Vaginal erbium laser for treatment of stress urinary incontinence: optimization of treatment regimen for a sustained long-term effect. Lasers Med Sci. 2022 Jun;37(4):2157-2164. doi: 10.1007/s10103-021-03474-z. Epub 2022 Jan 24.
    Results Reference
    derived

    Learn more about this trial

    Long-term Effectiveness of Non-ablative Er: YAG Laser for Treatment of Stress Urinary Incontinence (SUI)

    We'll reach out to this number within 24 hrs